Intelligent Investor

Admedus Ltd (ASX: AHZ) - Announcements

- Current share price for AHZ : $7.200

ASX company news and announcements for Admedus Ltd (AHZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Admedus Ltd (AHZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Admedus Ltd (AHZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Admedus Ltd (AHZ)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Appendix 3B 13 Jan 2020 2:01PM $0.115 $7.200 $7.640 risen by 6,160.87%
- Appendix 3B 11 Dec 2019 4:41PM $0.090 $7.200 $7.640 risen by 7,900%
- Update to LeMaitre Vascular deal 9 Dec 2019 10:12AM $0.092 $7.200 $7.640 risen by 7,726.09%
- Appendix 3B 26 Nov 2019 11:56AM $0.090 $7.200 $7.640 risen by 7,900%
- Response to ASX Price and Volume Query 19 Nov 2019 2:12PM $0.100 $7.200 $7.640 risen by 7,100%
- ADAPT Carve Out Financial Statements 31 Oct 2019 10:11AM $0.064 $7.200 $7.640 risen by 11,150%
- Appendix 4C - quarterly 31 Oct 2019 10:02AM $0.064 $7.200 $7.640 risen by 11,150%
- CardioCel and VascuCel LeMaitre deal clarification 15 Oct 2019 10:44AM $0.072 $7.200 $7.640 risen by 9,900%
- Reinstatement to Official Quotation 14 Oct 2019 10:00AM $0.060 $7.200 $7.640 risen by 11,900%
- CardioCel and VascuCel rights sold to LeMaitre Vascular 14 Oct 2019 10:00AM $0.060 $7.200 $7.640 risen by 11,900%
- Extension for Voluntary Suspension 30 Sep 2019 9:22AM $0.060 $7.200 $7.640 risen by 11,900%
- CARDIOCEL 3D APPROVED FOR SALE IN ISRAEL 4 Sep 2019 3:42PM $0.060 $7.200 $7.640 risen by 11,900%
- Appendix 3B 2 Sep 2019 6:58PM $0.060 $7.200 $7.640 risen by 11,900%
- Extension for Voluntary Suspension 2 Sep 2019 9:46AM $0.060 $7.200 $7.640 risen by 11,900%
- Appendix 4D and Half Yearly Financial Report 23 Aug 2019 3:33PM $0.060 $7.200 $7.640 risen by 11,900%
- Suspension from Official Quotation - Annual Listing Fee 22 Aug 2019 10:10AM $0.060 $7.200 $7.640 risen by 11,900%
- Response to ASX Appendix 4C Query 15 Aug 2019 6:53PM $0.060 $7.200 $7.640 risen by 11,900%
- Notice to terminate distribution agreement 8 Aug 2019 11:03AM $0.060 $7.200 $7.640 risen by 11,900%
- Change in substantial holding 7 Aug 2019 9:33AM $0.060 $7.200 $7.640 risen by 11,900%
- Extension for Voluntary Suspension 5 Aug 2019 9:30AM $0.060 $7.200 $7.640 risen by 11,900%
- Appendix 4C - quarterly 31 Jul 2019 5:53PM $0.060 $7.200 $7.640 risen by 11,900%
- Appendix 3B 16 Jul 2019 5:09PM $0.060 $7.200 $7.640 risen by 11,900%
- Extension for Voluntary Suspension 1 Jul 2019 10:30AM $0.060 $7.200 $7.640 risen by 11,900%
- POSITIVE DATA ON CARDIOCEL PUBLISHED IN LEADING JOURNAL 24 Jun 2019 1:56PM $0.060 $7.200 $7.640 risen by 11,900%
- Extension for Voluntary Suspension 4 Jun 2019 9:28AM $0.060 $7.200 $7.640 risen by 11,900%

26 - 50 of 444 results

Page 2 of 18

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.